Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [1] Core Views - The management is actively pursuing growth strategies, indicating a clear growth ambition alongside a new product cycle, which is expected to resonate positively with the company's performance [7] - The company is projected to achieve a significant turnaround in profitability, with a forecasted net profit of 276.77 million in 2025, representing a 615.21% year-on-year increase [7] - The report highlights strong revenue growth in the BNC and infant formula segments, with expected growth rates of 20-30% for infant formula and low single-digit growth for probiotics and nutritional products [7] Financial Projections - Total revenue is forecasted to reach 14,447 million in 2025, reflecting a 10.69% year-on-year increase [1] - The adjusted EBITDA and net profit are expected to grow by 2-6% and 15-25% respectively in 2025, with an overall adjusted net profit margin projected to be in the mid-single digits [7] - The company anticipates a cash balance exceeding 1.7 billion by 2025, which will support its debt reduction efforts and optimize interest expenses in 2026 [7] Valuation Metrics - The report provides a P/E ratio forecast of 28.84x for 2025, decreasing to 9.05x by 2027, indicating an attractive valuation as earnings improve [1][7] - The projected EPS for 2025 is 0.43, with further increases to 0.99 in 2026 and 1.37 in 2027 [1]

Investment Rating - The report maintains a "Buy" rating for H&H International Holdings (01112.HK) [1] Core Views - The management is actively pursuing growth strategies, and the company is expected to enter a new growth cycle driven by product innovation and market expansion [7] - The company has shown resilience with a strong recovery in profitability, with a projected net profit of 276.77 million in 2025, a significant turnaround from a loss in 2024 [7] - The report highlights the anticipated strong growth in the BNC and infant formula segments, with expected revenue growth rates of 20-30% for infant formula and low single-digit growth for probiotics and nutritional products [7] Financial Projections - Total revenue is projected to reach 14,447 million in 2025, with a year-on-year growth of 10.69% [1] - The adjusted net profit is expected to grow significantly, with projections of 276.77 million in 2025, 637.48 million in 2026, and 882.11 million in 2027, reflecting growth rates of 615.21% and 130.33% respectively [7] - The report anticipates a gradual improvement in the company's financial metrics, including an EBITDA increase to 2,077.71 million by 2027 [8]